Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by abrdn plc

abrdn plc increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 30.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 431,098 shares of the biotechnology company’s stock after purchasing an additional 101,253 shares during the period. abrdn plc owned 0.46% of Sarepta Therapeutics worth $53,935,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Riggs Asset Managment Co. Inc. increased its position in Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 125 shares during the period. Innealta Capital LLC acquired a new stake in Sarepta Therapeutics during the 2nd quarter worth approximately $31,000. New Covenant Trust Company N.A. purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $32,000. Nkcfo LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter worth about $43,000. Finally, UMB Bank n.a. raised its stake in shares of Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after buying an additional 197 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the subject of several recent research reports. Citigroup dropped their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Piper Sandler decreased their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $152.00 target price on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Two research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $130.21 on Wednesday. The firm has a fifty day moving average of $128.39 and a 200-day moving average of $132.61. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $12.31 billion, a P/E ratio of 1,183.73 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same period in the prior year, the company earned ($0.27) EPS. The firm’s revenue was up 38.9% on a year-over-year basis. As a group, analysts predict that Sarepta Therapeutics, Inc. will post 1.45 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers purchased 37,038 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.